二、募集资金专户开立情况 为了规范募集资金的管理和使用，保护投资者权益，本公司依照中国证券监 督管理委员会、上海证券交易所的有关规定，结合本公司实际情况，制定了《募 集资金使用管理办法》（以下简称管理办法），对公司募集资金的存放、使用及 使用情况的监管等方面做出了具体明确的规定，并按照管理制度的规定存放、使 用、管理资金。公司与保荐机构、募集资金专户监管银行签订了募集资金三方监 管协议，明确了各方的权利和义务。本次注销前公司募集资金专户的情况如下： | | | 1 | | | | 特殊制剂研发平台项目 | | | --- | --- | --- | --- | --- | | 北京阳光诺 | 招商银行股份 | | 药物创新研发平台项目 | | | 和药物研究 | 有限公司北京 | | 临床试验服务平台建设项 | 本次注 | | 股份有限公 | | 110943202110302 | 目 | 销 | | 司 | 大运村支行 | | 创新药物 研究平台 PK/PD | | | | | | 项目 | | | 北京阳光诺 | | | | | | | 兴业银行股份 | | | | | 和药物研究 | 有限公司北京 | ...

Group 1 - The stock price of Sunshine Nuohuo closed at 67.04 yuan on August 12, 2025, down by 1.62 yuan from the previous trading day [1] - The trading volume for the day was 270 million yuan, with a turnover rate of 3.60%, and the company's total market capitalization reached 7.508 billion yuan [1] - Sunshine Nuohuo specializes in pharmaceutical research services, covering the entire CRO industry chain, including drug discovery, pharmaceutical research, and clinical research [1] Group 2 - The overall performance of the medical services sector was poor on that day, with the CRO index dropping by 2.21% [1] - The net outflow of main funds for Sunshine Nuohuo was 9.6117 million yuan, accounting for 0.13% of the circulating market value; however, it maintained a net inflow over the past five trading days, totaling 34.8713 million yuan [1]

每经AI快讯，8月12日，CRO指数盘中显著回调，现跌2.21%。成分股普遍走弱，成都先导跌4.14%、金 凯生科跌3.84%、阳光诺和跌3.82%、益诺思跌3.31%、奥浦迈跌2.86%领跌。 （文章来源：每日经济新闻） ...

证券之星消息，8月11日医疗服务板块较上一交易日上涨1.71%，海特生物领涨。当日上证指数报收于 3647.55，上涨0.34%。深证成指报收于11291.43，上涨1.46%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300683 | 海特生物 | 55.27 | 8.67% | 13.17万 | | 7.08亿 | | 688621 | 阳光诺和 | 68.66 | 8.47% | 8.82万 | | · 5.81亿 | | 301201 | 诚达药业 | 29.56 | 7.57% | 10.19万 | | 2.94亿 | | 002173 | 创新医疗 | 18.72 | 6.36% | 147.62万 | | 27.39亿 | | 000504 | *ST生物 | 12.54 | 5.03% | 8.56万 | | 1.07亿 | | 300149 | 睿智医药 | 12.94 | 4.19% | 49.79万 | | 6.37亿 | ...

Fundraising Overview - The company has successfully raised a total of RMB 537.8 million through its initial public offering, with a net amount of RMB 467.18 million after deducting issuance costs [2] - The issuance involved 20 million shares at a price of RMB 26.89 per share, with a par value of RMB 1 per share [2] Fund Management - The company has established a management method for the use of raised funds, ensuring compliance with regulations from the China Securities Regulatory Commission and the Shanghai Stock Exchange [2] - A tripartite supervision agreement was signed with the sponsor and the bank managing the funds to clarify the rights and obligations of all parties involved [2] Account Closure - The company has closed certain special accounts for the raised funds as the related projects have been completed, transferring the remaining balances to other accounts [3] Major Asset Restructuring - The company is planning a major asset restructuring by issuing shares and convertible bonds to acquire 100% equity of Jiangsu Langyan Life Science Technology Holdings Co., Ltd [4] - This transaction is classified as a related party transaction since the target company is controlled by the company's major shareholder [4] Progress of the Restructuring - The company signed a letter of intent for the transaction on April 24, 2025, and subsequently suspended trading of its shares [5] - The board of directors approved the restructuring plan on May 12, 2025, and the company applied for the resumption of trading on May 13, 2025 [6] Ongoing Due Diligence - As of the latest announcement, the company is conducting audits, evaluations, and due diligence for the transaction, with further discussions on the transaction plan ongoing [7]

证券代码：688621 证券简称：阳光诺和 公告编号：2025-063 北京阳光诺和药物研究股份有限公司 关于筹划发行股份及可转换公司债券购买资产并募 集配套资金暨关联交易事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 员会第十七次会议、第二届董事会战略与 ESG 委员会第八次会议、第二届董事 会独立董事专门会议第六次会议审议通过了《关于公司发行股份及可转换公司债 券购买资产并募集配套资金暨关联交易方案的议案》《关于<北京阳光诺和药物 研究股份有限公司发行股份及可转换公司债券购买资产并募集配套资金暨关联 交易预案>及其摘要的议案》等与本次交易相关的议案。同日，公司向上海证券 交易所申请公司股票于 2025 年 5 月 13 日开市起复牌。具体内容详见公司于 2025 年 5 月 13 日刊登在上海证券交易所网站（www.sse.com.cn）的《北京阳光诺和 药物研究股份有限公司发行股份及可转换公司债券购买资产并募集配套资金暨 关联交易预案》《北京阳光诺和药物研究股份有限公司关于披露重大资产重组预 案的一般 ...

1 证券代码：688621 证券简称：阳光诺和 公告编号：2025-064 北京阳光诺和药物研究股份有限公司 关于注销部分募集资金专项账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意北京阳光诺和药物研究股份有限公司 首次公开发行股票注册的批复》（证监许可【2021】1629 号），同意公司首次 公开发行股票的注册申请，公司获准向社会公开发行人民币普通股 20,000,000 股。 每股面值为1元，每股发行价格为26.89元，本次发行募集资金总额537,800,000.00 元。上述募集资金总额扣除发行费用 70,618,507.55 元（相关费用均为不含税金 额）后，本次公司公开发行新股的募集资金净额 467,181,492.45 元，民生证券股 份有限公司已于 2021 年 6 月 16 日将扣除相关承销保荐费（不含税）人民币 47,402,000.00 元后的余款人民币 490,398,000.00 元汇入公司募集资金专户，大华 会计师事务所（特殊普通 ...

Group 1 - The innovative drug concept stocks experienced significant upward movement, with Rundu Co., Ltd. hitting the daily limit increase [1] - Haitian Pharmaceutical and Sunshine Nuohuo both rose over 10%, indicating strong market interest [1] - Other companies such as Huaren Health, Fuyuan Pharmaceutical, and Guangsheng Tang also saw notable gains, reflecting a broader trend in the sector [1]

Core Viewpoint - Sunshine Nuohuo's stock price experienced a decline on August 5, closing at 64.33 yuan, down by 2.21 yuan from the previous trading day [1] Company Overview - Sunshine Nuohuo is focused on the medical services sector, with operations including pharmaceutical research and clinical trials. The company is headquartered in Beijing and holds a significant market position in the pharmaceutical research service field [1] Stock Performance - On August 5, the opening price was 66.00 yuan, with a highest price of 66.00 yuan and a lowest price of 63.45 yuan. The trading volume was 62,636 hands, with a transaction amount of 403 million yuan [1] - The company currently has a price-to-earnings (P/E) ratio of 60.90 times and a price-to-book (P/B) ratio of 7.12 times [1] Capital Flow - On August 5, the net outflow of main funds for Sunshine Nuohuo was 31.608 million yuan, with a cumulative net outflow of 99.2964 million yuan over the past five trading days [1]

阳光诺和最新一期业绩显示，截至2025一季报，公司营业总收入2.31亿元、同比减少8.49%，归属净利 润2957.86万元，同比减少59.34%，扣非净利润2020.48万元，同比减少69.67%，流动比率1.635、速动比 率1.621、资产负债率51.76%。 金融界消息 截至2025年8月5日收盘，阳光诺和（688621）报收于64.33元，下跌3.32%，换手率5.59%， 成交量6.26万手，成交金额4.03亿元。 通过天眼查大数据分析，北京阳光诺和药物研究股份有限公司共对外投资了20家企业，参与招投标项目 25次，知识产权方面有商标信息25条，专利信息91条，此外企业还拥有行政许可22个。 资金流向方面，今日主力资金净流出3160.80万元，占比成交额7.85%。其中，超大单净流出2094.22万 元、占成交额5.2%，大单净流出1066.58万元、占成交额2.65%，中单净流出流入2102.46万元、占成交 额5.22%，小单净流入1058.34万元、占成交额2.63%。 来源：金融界 天眼查商业履历信息显示，北京阳光诺和药物研究股份有限公司，成立于2009年，位于北京市，是一家 以从事研究和 ...